Prednisolone Sodium Phosphate | Prednisolone Tablet, Orally Disintegrating while Breastfeeding

It is recommended to breastfeed exclusively for six months and then while introducing to other food sources extend it to twelve months. In this duration most mothers will need help of some sort of medication, It could be for short term like could and flue or it could be something chronic like Arthritis or Diabetes and here comes the question of safety of medication in use. In this post we will figure out what is Prednisolone Sodium Phosphate | Prednisolone Tablet, Orally Disintegrating and whether its safe to use Prednisolone Sodium Phosphate | Prednisolone Tablet, Orally Disintegrating while nursing or not.

Prednisolone sodium phosphate orally disintegrating tablets are indicated in the treatment of the following diseases or conditions: Prednisolone sodium phosphate is a corticosteroid indicated •as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation (1) •for the treatment of certain endocrine conditions (1) •for palliation of certain neoplastic conditions (1) 1.1 Allergic Conditions Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: •Atopic dermatitis •Drug hypersensitivity reactions •Seasonal or perennial allergic rhinitis •Serum sickness 1.2 Dermatologic Diseases •Bullous dermatitis herpetiformis •Contact dermatitis •Exfoliative erythroderma •Mycosis fungoides •Pemphigus •Severe erythema multiforme (Stevens-Johnson Syndrome) 1.3 Endocrine Conditions •Congenital adrenal hyperplasia •Hypercalcemia of malignancy •Nonsuppurative thyroiditis •Primary or secondary adrenocortical insufficiency: hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable. 1.4 Gastrointestinal Diseases During acute episodes in: •Crohn’s Disease •Ulcerative colitis 1.5 Hematologic Diseases •Acquired (autoimmune) hemolytic anemia •Diamond-Blackfan anemia •Idiopathic thrombocytopenic purpura in adults •Pure red cell aplasia •Secondary thrombocytopenia in adults 1.6 Neoplastic Conditions For the treatment of: •Acute leukemia •Aggressive lymphomas 1.7 Nervous System Conditions •Acute exacerbations of multiple sclerosis •Cerebral edema associated with primary or metastatic brain tumor, craniotomy or head injury 1.8 Ophthalmic Conditions •Sympathetic ophthalmia •Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids 1.9 Conditions Related to Organ Transplantation •Acute or chronic solid organ rejection 1.10 Pulmonary Diseases •Acute exacerbations of chronic obstructive pulmonary disease (COPD) •Allergic bronchopulmonary aspergillosis •Aspiration pneumonitis •Asthma •Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy •Hypersensitivity pneumonitis •Idiopathic bronchiolitis obliterans with organizing pneumonia •Idiopathic eosinophilic pneumonias •Idiopathic pulmonary fibrosis Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics •Symptomatic sarcoidosis 1.11 Renal Conditions To induce a diuresis or remission of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 1.12 Rheumatologic Conditions As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: •Acute gouty arthritis During an exacerbation or as maintenance therapy in selected cases of: •Ankylosing spondylitis •Dermatomyositis/polymyositis •Polymyalgia rheumatica/temporal arteritis •Psoriatic arthritis •Relapsing polychondritis •Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) •Sjogren’s syndrome •Systemic lupus erythematosus •Vasculitis 1.13 Specific Infectious Diseases •Trichinosis with neurologic or myocardial involvement •Tuberculous meningitis with subarachnoid block or impending block, (used concurrently with appropriate antituberculous chemotherapy

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers Prednisolone is secreted in human milk. Reports suggest that prednisolone concentrations in human milk are 5% to 25% of maternal serum levels, and that total infant daily doses are small, about 0.14% of the maternal daily dose. Therefore, caution should be exercised when prednisolone is administered to a nursing woman. High doses of corticosteroids for long periods could potentially produce problems in infant growth and development and interfere with endogenous corticosteroid production. The risk of infant exposure to prednisolone through breast milk should be weighed against the known benefits of breast-feeding for both the mother and baby. If prednisolone must be prescribed to a breast-feeding mother, the lowest dose should be prescribed to achieve the desired clinical effect.